ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1601

The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as  Interferon-α In Systemic Lupus Erythematosus

Taku Yoshio1, Hiroshi Okamoto2, Kazuhiro Kurasawa3, Yoshiaki Dei4, Shunsei Hirohata5 and Seiji Minota6, 1Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, 2Minami-Otsuka Institute of Thechnology, Minami-Otsuka Clinic, Tokyo, Japan, 3Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, 4Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi-ken, Japan, 5Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, 6Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: central nervous system involvement, IL-6, Interferons and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:  IgG-Immune complexes (IC) formed by CSF autoantibodies in patients with neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) has reported to stimulate the production of interferon (IFN)-α, IL-8, IP-10, MCP-1 in a bioassay containing plasmacytoid dendritic cells and a source of antigens.The pathological roles of these cytokines/chemokines in the CSF has been reported in patients with NPSLE. These results suggest that IgG-IC in the CSF may have pathogenic roles in central NPSLE.

We investigated whether IgG-IC are present in the CSF of patients with central NPSLE and correlated with cytokines/chemokines such as IFN-a levels in the CSF.

Methods: 50 SLE patients, of whom the CSF samples were obtained, were enrolled. Of 50 SLE patients, 29 had central NPSLE and the reminder 21 did not have central NPSLE. The levels of IgG-IC in the CSF samples were measured by ELISA kits. The levels of IL-6, IL-8, IP-10, MCP-1, and G-CSF in the CSF samples were measured by Bio-Plex Pro Assays. IFN-α in the CSF samples were measured by ELISA kits. Antiribosomal P protein antibody (anti-P) titers in the CSF samples were measured by ELISA using recombinant ribosomal P0 protein as the antigen.

Results:   CSF IgG-IC levels in 29 patients with central NPSLE were significantly higher than in 21 patients without central NPSLE (mean ± SD, median [range]; 3.75 ± 4.80 μg/ml, 1.28 [0.09 – 18] vs. 1.01 ± 1.40 μg/ml, 0.49 [0.09 – 6.38]; p = 0.047). The CSF levels of IL-6, IL-8, IP-10, MCP-1, and G-CSF and CSF anti-P titers in 29 patients with central NPSLE were significantly higher than those in 21 patients without central NPSLE, respectively (275.1 ± 595.9 pg/ml, 17.4 [1.9 – 2882.2] vs. 11.6 ± 12.8 pg/ml, 5.0 [1.3 – 45.2]; p = 0.007, 482.5 ± 1697.6 pg/ml, 99.2 [17.7 – 9233.7] vs. 58.5 ± 81.2 pg/ml, 31.0 [6.3 – 366.8]; p = 0.004, 8988.0 ± 15406.2 pg/ml, 3248.2 [228.7 – 76941.5] vs. 2988.3 ± 4126.9 pg/ml, 1137.8 [427.6 – 15765.1]; p = 0.034, 555.7 ± 481.0 pg/ml, 387.6 [35.6 – 2008.5] vs. 284.3 ± 161.5 pg/ml, 265.1 [55.6 – 664.6]; p = 0.021, 71.5 ± 156.0 pg/ml, 33.4 [0.81 – 779.4] vs. 15.5 ± 24.8 pg/ml, 3.9 [0 – 102.7]; p = 0.009 and 6.90 ± 9.36 CSFU/ml, 2.6 [0 – 31.0] vs. 3.75 ± 9.25 CSFU/ml, 0.95 [0.14 – 41.3]; p = 0.021). Unexpectedly, CSF IFN-α levels in patients with central NPSLE were not significantly higher than in patients without central NPSLE (13.1 ± 58.9 pg/ml, 0 [0 – 314.0] vs. 0.17 ± 0.75 pg/ml, 0 [0 – 3.4]; p = 0.565). Discriminant analysis showed the most significant association between IgG-IC levels in the CSF and the presence of central NPSLE (P = 0.02). However, CSF IgG-IC levels in these patients were not significantly correlated with CSF levels of any of the studied cytokines/chemokines.  The significant positive association between CSF IgG-IC levels and CSF anti-P titers was not observed in these patients.

Conclusion:  The intrathecal IgG-IC might have important roles in the pathogenesis of central NPSLE. But the intrathecal IgG-IC was not associated with the intrathecal production of cytokines/chemokines studied in this study.


Disclosure:

T. Yoshio,
None;

H. Okamoto,
None;

K. Kurasawa,
None;

Y. Dei,
None;

S. Hirohata,
None;

S. Minota,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-presence-of-igg-immune-complexes-in-the-cerebrospinal-fluids-is-associated-with-central-neurocychiatric-manifestatin-but-not-with-intrathecal-production-of-proimmflammatory-cytokineschemokines-su/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology